|
Independent Study Is Good News for Lilly’s Solanezumab in Early Alzheimer’s Treatment
An independent analysis by the Alzheimer’s Disease Cooperative Study (ADCS) has found higher beta amyloid levels in the blood of patients treated with Eli Lilly’s Alzheimer’s candidate solanezumab compared with placebo.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives